| Recruiting | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced NCT07217171 | EvolveImmune United, Inc | Phase 1 |
| Recruiting | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ So NCT07169734 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Sta NCT06543576 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors NCT06747585 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell NCT05910827 | Hummingbird Bioscience | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subj NCT05827614 | Boundless Bio, Inc. | Phase 1 |
| Active Not Recruiting | Primary Cervical Cancer Screening by Self-sampling HPV Test NCT05613283 | Peking University People's Hospital | — |
| Active Not Recruiting | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma NCT07147361 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | — |
| Unknown | Clinical Evaluation of Detection of High Risk HPV in Urine NCT05210348 | Peking University People's Hospital | — |
| Unknown | Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma NCT05013268 | Ruijin Hospital | Phase 1 |
| Not Yet Recruiting | Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma NCT04976478 | Peking University Third Hospital | — |
| Unknown | Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell NCT04678791 | Peking University Third Hospital | N/A |
| Active Not Recruiting | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid T NCT03983954 | NeoTX Therapeutics Ltd. | Phase 1 |
| Completed | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive S NCT03738228 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcino NCT06781073 | Biotech Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) Duri NCT02466971 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer NCT02562729 | Shanghai Gynecologic Oncology Group | Phase 2 |
| Completed | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer NCT02164461 | Advaxis, Inc. | Phase 1 |
| Completed | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cance NCT02020707 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical NCT01649089 | GOG Foundation | N/A |
| Completed | Oral Rigosertib for Squamous Cell Carcinoma NCT01807546 | Traws Pharma, Inc. | Phase 2 |
| Completed | Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer NCT01693783 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Hybrid PET/MR in the Therapy of Cervical Cancer NCT01759355 | UNC Lineberger Comprehensive Cancer Center | — |
| Completed | Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix NCT01365156 | M.D. Anderson Cancer Center | Phase 3 |
| Completed | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Re NCT01266447 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Can NCT01026792 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurre NCT00803062 | National Cancer Institute (NCI) | Phase 3 |
| Completed | FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer NCT00559377 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Th NCT00416455 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer NCT00054444 | Gynecologic Oncology Group | Phase 1 |
| Completed | Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer NCT00499031 | Gynecologic Oncology Group | Phase 2 |
| Completed | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be NCT00389974 | National Cancer Institute (NCI) | Phase 2 |
| Completed | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer NCT00309959 | Gynecologic Oncology Group | Phase 2 |
| Terminated | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer NCT00262821 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer NCT00217633 | Gynecologic Oncology Group | Phase 2 |
| Completed | Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage NCT00104910 | Gynecologic Oncology Group | Phase 1 |
| Terminated | Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer NCT00070317 | Gynecologic Oncology Group | N/A |
| Completed | Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer NCT00068549 | Gynecologic Oncology Group | Phase 1 |
| Completed | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recu NCT00064077 | Gynecologic Oncology Group | Phase 3 |
| Completed | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer NCT00057863 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix NCT00025233 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix NCT00031993 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Ane NCT00017004 | Gynecologic Oncology Group | Phase 3 |